The company said its total revenue for Q3 2025 was $1.0 billion, a 45% decrease from $1.9 billion in the same period of 2024. It said net product sales fell $847 million (47%), mainly due to lower COVID vaccine sales.

1. 01

   The company said its total revenue for Q3 2025 was $1.0 billion, a 45% decrease from $1.9 billion in the same period of 2024. It said net product sales fell $847 million (47%), mainly due to lower COVID vaccine sales.

2. 02

   Moderna said COVID vaccine sales were $971 million in Q3 2025, including $781 million in the U.S. and $190 million internationally. It said mRESVIA sales were $2 million in the same quarter.

3. 03

   Moderna reported a net loss of $(200) million and a loss per share of $(0.51) for Q3 2025. For Q3 2024, it reported net income of $13 million and earnings per share of $0.03.

4. 04

   The company said it narrowed its revenue outlook range for 2025 to $1.6 to $2.0 billion from $1.5 to $2.2 billion. It also said its year-end cash and investments balance for 2025 is projected at $6.5 to $7 billion, up from its previous expectation of about $6 billion.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.